Picture EBD Group BioTech Showcase 2020 San Francisco BEU2020 650x76px
Document › Details

InterAx Biotech AG. (1/15/19). "Press Release: InterAx Biotech Closes Financing Round of CHF 3 Million and Appoints New Member of the Board".

Organisations Organisation InterAx Biotech AG
  Organisation 2 Falcon III Ventures
Products Product drug discovery software
  Product 2 venture capital
Index terms Index term InterAx Biotech–SEVERAL: investment, 201901 financing round CHF3m led by Falcon III Ventures + Investiere
  Index term 2 InterAx Biotech–Verve Capital Partners: investment, 201901 financing round totalling CHF3m incl co-lead investor Investiere
Person Person Ernst, Bettina (InterAx Biotech 201901– Non-executive Board Member)

InterAx Biotech, pioneering computational pharmacology for drug discovery, has closed a financing round of CHF 3 million. The investment round was led by Falcon III Ventures and investiere. The new funds will be used to accelerate commercialization of the technology platform which enables intelligent drug candidate design and selection.

InterAx appoints Dr. Bettina Ernst as a new member of the board of directors. She brings in additional extensive and valuable experience from the biotech and pharmaceutical industry.

Record changed: 2019-01-22


Picture [LSA] – The Business Web Portal 650x89px

More documents for InterAx Biotech AG

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group BioTech Showcase 2020 San Francisco BEU2020 650x76px

» top